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www.embomolmed.org EMBOA decade has elapsed since the concept of oncogene addiction was first proposed. It
postulates that – despite the diverse array of genetic lesions typical of cancer – someours rely on one single dominant oncogene for growth and survival, so that
ibition of this specific oncogene is sufficient to halt the neoplastic phenotype. A
ge amount of evidence has proven the pervasive power of this notion, both in
sic research and in therapeutic applications. However, in the face of such a
nsiderable body of knowledge, the intimatemolecular mechanismsmediating this
enomenon remain elusive. At the clinical level, successful translation of the
cogene addiction model into the rational and effective design of targeted
rapeutics against individual oncoproteins still faces major obstacles, mainly
e to the emergence of escape mechanisms and drug resistance. Here, we offer
overview of the relevant literature, encompassing both biological aspects and
ent clinical insights. We discuss the key advantages and pitfalls of this concept
d reconsider it as an illustrative principle to guide post-genomic cancer research
d drug development.Introduction
Coordinated efforts by the Interna-
tional Cancer Genome Consortium
and other Institutions have started to
reveal the complex and heterogeneous
‘genomic landscapes’ of many human
cancer types with unprecedented accu-
racy (Hudson et al, 2010; Stratton et al,
2009). A variegate repertoire of genetic
aberrations – including point muta-
tions, small insertions/deletions, gene
amplifications and chromosomal rear-
rangements – leads to a ‘picture’ in
which recurrent lesions in dominantly
acting, driver oncogenes and tumoursuppressor genes emerge as ‘peaks’ over a flatter line of
infrequently occurring, passenger mutations (the ‘hills’; Plea-
sance et al, 2010; Velculescu, 2008; Wood et al, 2007). The latter
probably represent non-adaptive – yet potentially fitness-
increasing – mutations in genes involved in widely different
cellular functions, acquired at a certain point during tumour
evolution. This picture has supported the classic notion of
cancer as ‘a hundred of diseases’, raising both hopes and
concerns: while discovery strategies aimed to the identification
of novel driver oncogenic lesions are likely to enrich theancer Research and
l, Candiolo (Torino),
þ 39 011 993 3225;
Mol Med 3, 623–636catalogue of therapeutic targets, the task of developing therapies
suitable for successful treatment of the full spectrum of cancers,
with all their intrinsic heterogeneity, can be easily seen as
Herculean and almost impossible (Chin et al, 2011; Chin and
Gray, 2008). Yet, the success of therapies that target specific
oncoproteins in molecularly defined subsets of cancer patients
has provided formal and practical demonstration that, at least in
some tumour types, abrogation of the function of individual
oncogenic products is sufficient to induce tumour regression or
stabilization. Hence, it appears that not all peaks within a
tumour have been created equal, and many can be over-
shadowed by one (Haber et al, 2011; Macconaill and Garraway,
2010).
As often, the reversal of the cancerous phenotype induced by
the therapy observed in the clinic was predicted by mechanistic
studies in the laboratory. Using both in vitro and in vivo models 2011 EMBO Molecular Medicine 623
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Table 1. Experimental examples of oncogene addiction
Oncogene Models
In vitro In vivo References
MYC RNAi in haematopoietic cells Conditional MYC-driven mouse models of
leukaemia
Felsher and Bishop (1999),
Loke et al (1988)
H-RAS, K-RAS Farnesyl transferase inhibitors in H-RAS-
transformed and K-RASmut expressing cell lines
Conditional K-RASmut-driven mouse model of
lung cancer
Fisher et al (2001),
Kohl et al (1994)
ABL Small-molecule inhibitor in BCR-ABL expressing
cell lines
Systemic antisense oligodeoxynucleotides
delivery in mouse model of CML
Druker et al (1996),
Skorski et al (1994)
HER2 RNAi in erbB-2 amplified breast carcinoma
cell lines
Conditional erbB-2-driven mouse model of
mammary cancer
Colomer et al (1994),
Moody et al (2002)
EGFR Ribozyme against aberrant EGFR-expressing
cell line
mAB in EGFR-amplified xenografts Luwor et al (2001),
Yamazaki et al (1998)
RNAi, RNA interference; mAB, monoclonal antibody.
624of gain-of-function tumourigenesis, it was found that acute
inactivation of transforming oncogenes leads to cell-cycle arrest,
differentiation or apoptosis, depending on tissue contexts
(Table 1; reviewed in Sharma and Settleman, 2007; Weinstein
and Joe, 2006). One evident drawback of these experiments is
that tumour dependency was induced artificially, through
ectopic introduction of a hyperactive initiating oncogene in a
normal tissue background. This is of course far from the
evolutionary trajectory of spontaneous human tumours, in which
the dominant oncogene does not necessarily correspond to the
initiating driver alteration. However, the striking responses
observed in these cellular and animal models anticipated those
that would be observed, years later, in human patients treated
with targeted therapies against individual oncoproteins.
The compelling concept proposed to account for these
evidences is known as oncogene addiction. This definitionGlossary
Cell-autonomous
A genetic trait in multicellular organisms in which only genotypically
mutant cells exhibit themutant phenotype. Conversely, a non-autonomous
trait is one in which genotypically mutant cells cause other cells (regardless
of their genotype) to exhibit a mutant phenotype.
Chimeric protein
A hybrid protein encoded by a nucleotide sequence that resulted from the
fusion of two or more complete or partial genes.
Chronic phase, blast crisis (CML)
Chronic phase is the first phase of CML progression and presents with mild
or even absent symptoms. Blast crisis is the last stage of CML, which
behaves like an acute leukaemia and in which the number of blast cells is
elevated in bone marrow and blood.
Deep sequencing
Technique to analyse nucleotide sequences with increased range,
complexity, sensitivity and accuracy compared to standard, first-genera-
tion sequencing techniques.
Feedback loops
The causal pathways that lead from the initial generation of the feedback
signal back to subsequently modify the event.
 2011 EMBO Molecular Medicinewas first introduced by Bernard Weinstein in 2000, with
particular reference to the observation that some cyclin D-
overexpressing cancers reverse their malignant phenotype upon
cyclin-D depletion by means of RNA interference (RNAi;
Weinstein, 2000; Weinstein, 2002). In its original version, it
postulated that cancer cells display either oncogene addiction
(i.e. dependence on the prolonged activity of oncogenes) or gene
hypersensitivity (i.e. sensitivity to the restored biochemical
function of tumour suppressor genes); this was proposed to be
due to the paradoxical, ‘bizarre circuitry’ typical of tumour cells,
which in turn is the consequence of the altered mechanisms
of cellular homeostasis fuelled by tumour formation and
evolution. After more than 10 years, the oncogene addiction
concept retains full validity and remains a paradigmatic
example of how mechanistic studies can have immediate
translational relevance.Fitness
High potential for survival under defined circumstances.
Genetic drift
Change in the frequency of a genetic variant, which takes place only by
chance.
Genetic instability
A set of diverse genetic events, which cause either temporary or permanent
changes within the genome.
High-throughput (Screening)
The process duringwhich batches of compounds, expression libraries or RNA-
interference libraries are tested for a defined activity on a certain target.
Open reading frame
A DNA sequence that contains a start codon but no stop codon and can
potentially be translated into a protein.
Orthologue
Enzymes, which have the same activity.
Patient stratification
Definition of subsets of patients, which would benefit from a given therapy,
with a shared biological characteristic identified with the use of biomarkers.
Transcriptional signature
Set of expressed mRNAs, which define the presence of a certain condition.
EMBO Mol Med 3, 623–636 www.embomolmed.org
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Essentially, three models have been put forward to elucidate the
mechanisms of oncogene addiction at the molecular level. All of
them take into account cell-autonomous (cancer-specific)
properties and are known as (i) genetic streamlining, (ii)
oncogenic shock and (iii) synthetic lethality (SL). Initially
speculative, these theories were each experimentally validated
and can explain different but complementary facets of this
phenomenon.
Genetic streamlining
The genetic streamlining hypothesis stems from the well-
established notion that cancer cells undergo constant genetic
drift as a consequence of the selective pressure exerted by the
tumourigenic process and by the tumour microenvironment.
Because of this, cancer cells are thought to lose (or, better,
actively dismiss) any cellular function that has proved to be non-
essential for cell viability or does not provide any increase inGenetic streamlining
Cell cycle
arrest
and/or 
apoptosis
Proliferation
and/or
survival 
Oncogenic shock
A B
Death
Death
Survival
Survival
Figure 1. Models of oncogene addiction.
A. The ‘genetic streamlining’ theory postulates that non-essential pathways (top, l
pathways (red) are not surrogated by compensatory signals. Upon abrogation
cell-cycle arrest or apoptosis (bottom, red to yellow shading).
B. In the ‘oncogenic shock’ model, addictive oncoproteins (e.g. RTKs, red triangle) tr
pathway, respectively). Under normal conditions, the pro-survival outputs domi
receptor, the rapid decline in the activity of survival pathways (dashed lines, bo
last longer and eventually lead to apoptotic death.
C. Two genes are considered to be in a synthetic lethal relationship when loss of on
panel, biochemical inactivation of pathway A (grey) has no effect on cell viab
substrate or effector (yellow), has compensating activity. When the integrity
function is lost and again cancer cells may experience cell cycle arrest or apo
www.embomolmed.org EMBO Mol Med 3, 623–636cellular fitness (‘genome degeneration’). At the molecular level,
this occurs presumably through a mutational burden of non-
adaptive alterations or epigenetic modifications (‘genetic load’).
When the pressure exerted by the tumour microenvironment or
by tumour-autonomous features remains constant, the genetic
load in non-essential genes will have little effect on cell growth
dynamics (Kamb, 2003). However, the widespread silencing of
subsidiary functions renders cancer cells much more susceptible
to acute perturbations: sudden changes in the composition of the
surrounding stroma or inhibition of one or more of the pathways
still active in cancer cells lead to rapid reduction in cellular
fitness and collapse (Fig 1A). Theoretically, this process may
produce an opposite outcome: an initially non-adaptive
mutation can coexist as a passenger alteration along with
driver mutations in the genome of a cancer cell until a new
selective force – for example drug exposure – unleashes its
potential to increase biological fitness in that particular
circumstance; this, in some instances, can foster the emergence
of resistant clones (see below).A B
A B
Synthetic lethality
Receptors
(e.g. RTKs)
Signalling
transducers/
effectors 
(e.g. TKs, TFs, 
enzymes)
Biochemical
interactions
Inactivation
of addictive 
oncoprotein
Addictive
pathway
Inactive
receptor/
transducer
C
Substrate/
function
ight grey) are inactivated during tumour evolution, so that dominant, addictive
of dominant signals, there is a collapse in cellular fitness and cells experience
igger at the same time pro-survival and pro-apoptotic signals (top, red and blue
nate over the pro-apoptotic ones (top), but following blockade of the addictive
ttom) subverts this balance in favour of death-inducing signals, which tend to
e or the other is still compatible with survival but loss of both is fatal. In the top
ility because pathway B (red), which converges at some point on a common
of pathway B is disrupted (bottom), the common downstream biochemical
ptosis.
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626Inactivation of signalling pathways in cancer cells after
genetic drift may also occur at the biochemical or transcriptional
levels as a consequence of chronic oncogenic signalling. Indeed,
the unrelenting activity of dominant oncogenes is likely to be
counteracted by a certain extent of reactive adaptation,
including activation of compensatory pathways and positive
or negative feedback loops. Using phosphoproteomic and gene
expression profiling, we have recently demonstrated the
presence of ‘sensitive’ and ‘indifferent’ pathways in cell lines
addicted to the MET oncogene – encoding the Met tyrosine
kinase receptor for hepatocyte growth factor (HGF) – or to
epidermal growth factor receptor (EGFR). Met or EGFR
inhibition in these settings results in the selective decline of
RAS- and PI3K-dependent cascades, whilst many other signals
known to affect Met- and EGFR-driven proliferation in non-
addicted cells – including JNK, p38, STATs and NF-kB – remain
active or exhibit scant responses (Bertotti et al, 2009). In the
context of genetic streamlining, this piece of information
corroborates the notion that cancer cells host large arrays of
indolent and functionally neutral pathways and small ensem-
bles of functionally active, self-sufficient transducers. The
presence of only a limited subset of operational signalling nodes
and the absence of buffering circuits reveal the vulnerability of
the oncogene addiction state.
Oncogenic shock
Settleman and colleagues have proposed a model referred to as
‘oncogenic shock’. The fundamental premise to this concept is
that most dominant oncogenes are able to sustain at the same
time both pro-survival and pro-apoptotic signals (Sharma and
Settleman, 2007). This duality is an in-built property of normal
cells, in which strong oncogenic insults can counteract excessive
pro-mitogenic signals induced by the same molecule through
concomitant induction of apoptosis. In transformed cells, this
intrinsic apoptotic defense is disabled for many reasons,
including the fact that the pro-survival signals that emanate
from hyperactive oncoproteins tend to dominate over the
parallel pro-apoptotic outputs (Fig 1B). A variety of experi-
mental data, collected in diverse cellular and in vivo transgenic
models, is in favour of this notion: for example the MYC
oncogene displays apoptosis-inducing properties in low-serum
conditions (Evan et al, 1992), which can be inhibited by
overexpression of the anti-apoptotic BCL2 protein (Bissonnette
et al, 1992) or PI3K/AKT pathway activation (Kauffmann-Zeh
et al, 1997). In normal physiology, the pro-apoptotic function of
MYC is apparent during development, as it causes the negative
selection of T lymphocytes upon antigen stimulation (Shi et al,
1992). Similarly, continued overexpression of the RAS or RAF
oncogenes in primary human cells induces cell cycle arrest
through activation of the MAPK family members p38 and JNK,
which in turn induce transcriptional upregulation of p53 or the
cyclin-dependent kinase (CDK) inhibitors p16 and/or p21
(Fanton et al, 2001; Zhu et al, 1998). As an alternative to
active induction of apoptosis, some cells react to relentless
oncogenic signalling by entering a state of senescence, that is an
irreversible condition of post-mitotic dormancy. In vitro and in
vivo models have shown that hyperproliferating cells accumu- 2011 EMBO Molecular Medicinelate genomic lesions such as DNA double strand breaks (DSB), a
process known as ‘replication stress’. In turn, DSBs engage the
DNA damage response machinery, which activates the proto-
typical effector ataxia telangiectasia mutated (ATM); this
converges on either p53 or p21, triggering the proliferation
blockade that typifies the senescent phenotype (Bartkova et al,
2006; Di Micco et al, 2006; Halazonetis et al, 2008).
The oncogenic shock hypothesis relies on the experimental
observation that targeted disruption of signal-generating
oncoproteins results in differential kinetics of downstream
signal decay: anti-apoptotic effectors (such as ERKs, AKT and
STATs) display rapid diminution of activity; conversely, death-
inducing molecules (namely p38) display delayed accumula-
tion. This temporal imbalance has been demonstrated in a
variety of cellular systems driven by oncogenically active
tyrosine kinases, including BCR-ABL, SRC and EGFR (Sharma
et al, 2006; Sharma and Settleman, 2010b). The oncogenic shock
hypothesis deserves at least two comments. First, it postulates
that the apoptotic response observed following abrogation of
addictive oncoproteins is an active process of signal-mediated
induction of cell death; this is in contrast to the passive
occurrence of signal deprivation predicted in the genetic
streamlining model. Second, the ‘potency’ of the oncogenic signal
in generating pro-survival and pro-apoptotic outputs seems to be
more crucial than the temporal appearance of the dominant
genetic lesion. While it can be intuitive to think that an initiating
oncogene will be more influential as a dominant alteration than
genetic lesions occurring subsequently during tumour evolution,
we can also reasonably argue that addictive oncogenes with
powerful pro-apoptotic activity are likely to arise late during the
tumour’s natural history, when at least some apoptotic safeguards
have been disengaged; otherwise, cells would die, and oncogene
hyperactivity would be negatively selected.
Synthetic lethality
The theory of SL states that a gene A is in a synthetic lethal
relationship with a gene B when loss of function of either gene A
or gene B is fully compatible with cell viability, whereas, loss of
activity of both A and B gene products is lethal for the cell
(Kaelin, 2005). This notion is rather intuitive when genes A and
B belong to alternative metabolic (enzymatic) chains with a
common end-product; but, at least in principle, it can also be
applied to signalling axes driving more sophisticated and
integrated cellular functions, such as survival and proliferation
(Fig 1C). The concept of SL dates back to the beginning of the
last century and was initially applied to account for experi-
mental data obtained in single-celled organisms, such as
bacteria and yeast. In the past decade, it has been exploited
for the characterization of orthologue enzymes involved in
certain metabolic pathways in multi-cellular model organisms
(Caenorhabditis elegans, Drosophila melanogaster) and, more
recently, it has been extended to human tumour cell lines
(Brough et al, 2011; Nijman, 2011). In cancer, SL is proposed to
occur when alteration of a gene (e.g. its genetic silencing or
pharmacologic inactivation) results in cell death only in the
presence of another non-lethal genetic alteration (e.g. a cancer-
associated mutation). Because the gene, that is synthetic lethalEMBO Mol Med 3, 623–636 www.embomolmed.org
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Davide Torti and Livio Trusolinoin combination with the cancerous mutation is usually in its
wild-type form, SL is also defined as ‘non-oncogene addiction’.
The SL working hypothesis led to the discovery of the
synthetic lethal interaction between the BRCA1 and/or BRCA2
gene products and [poly(ADP-ribose)-polymerase] PARP-1
protein (Lord and Ashworth, 2008). BRCA1 and BRCA2 have
a key role in homologous recombination (HR; Fig 2A), anPol-β + DNA ligase 
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Figure 2. Modes of DNA damage repair.
A. HR safeguards genome integrity in late S/G2 phases of the cell cycle and reli
template to guide repair of the damaged strands. Exonuclease activity produce
DNA break (top). Each of the two ssDNA ends pair with complementary sequ
represented here for simplicity); elongation is then performed by DNA polyme
ssDNA ends, further elongation and, ultimately, ligation give rise to the wild-typ
machinery.
B. BER senses chemically altered bases (b) with aminimal effect on double helix to
(middle top); this is in turn excised by an apurinic/apyrimidinic endonuclease (A
replaces the missing nucleotide, which is finally ligated to reconstitute the co
C. When homologous sequences are not available as templates, the ssDNA ends
pairs. This event if followed by filling of the gaps in each strand and ligation of a
system lacks some of the bases originally present in the undamaged DNA an
www.embomolmed.org EMBO Mol Med 3, 623–636important pathway for DNA damage repair, and their inactiva-
tion results in defective restoration of DNA DSBs (see above).
Single-strand breaks (SSBs) must also be repaired in BRCA-
deficient cells, because SSBs can turn into lethal DSBs following
DNA replication. The DNA repair pathway principally involved
in repairing SSBs is base-excision repair (BER; Fig 2B), and one
of the proteins essential for BER is PARP-1 (Rouleau et al, 2010).Single strand resection
by exonuclease 
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Chances to have limited
base complementarity
Filling in of single strand gaps
dsDNA break
Dribose-P moiety
+ base B
Chemically altered base
reestablishs
ence
Pol-β + DNA ligase reestablishs
correct sequence
pair (BER) Non-homologous end joining (NHEJ)
C
se cleaves
sugar
 cleaves
ay 
3’
5’
3’
5’
3’
5’
3’
5’
5’
3’
3’
5’
5’
3’
3’
5’
5’
3’
3’
5’
5’
3’
3’
5’
5’
3’
3’
5’
5’
3’
3’
5’
es on the ability to use the recently formed sister chromatids as a
s two single-stranded (ss) DNA ends, one at each side of a double-strand (ds)
ences of the sister chromatid (unwinding of sister chromatids is not
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e sequence. BRCA1 and BRCA2, among many other proteins, are part of the HR
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628It has been demonstrated that, when BER is inactivated (e.g. as a
consequence of PARP1 inhibition), BRCA-deficient cells are
unable to repair the DSBs that evolve from SSBs, and this leads
to deadly defects in the genome (Bryant et al, 2005; Farmer et al,
2005). Interestingly, acquired resistance to PARP inhibitors in
cells with BRCA2 loss-of-function alterations may result from
late ‘reverting’ mutations, that is new deletions in the context of
the BRCA2 gene that restore the normal open reading frame
abrogated by the original genetic lesion, thus rendering the cells
once again capable to perform HR (Edwards et al, 2008; Sakai
et al, 2008). Of note, two studies recently suggested an
alternative route for restoration of HR competence in BRCA1-
deleted cells (Bouwman et al, 2010; Bunting et al, 2010).
Tumour protein p53 binding protein 1 (TP53BP1, also known as
53BP1) is a component of the non-homologous end joining
(NHEJ) repair system (Fig 2C), which acts by binding to
chromatid breaks and triggers the formation of aberrant fusions
between heterologous chromosomes. These fusion products can
represent ‘toxic’ rearrangements and negatively affect cell
viability. Mechanistically, 53BP1 blunts the ATM-mediated
resection of the broken strands, ultimately impeding HR
(Bunting et al, 2010). HR is the preferred repair type for DSBs
in wild-type cells, whereas, in BRCA1-deficient cells (in which
normal HR is compromised) the balance switches towards the
NHEJ system. Suppression of residual HR function, for example
through PARP inhibition, further enhances the ‘toxic’ switch to
NHEJ, suggesting that neutralization of NHEJ might alleviate
generalized DNA damage and counteract the effects of PARP
inhibition. Indeed, RNAi-mediated depletion of 53BP1 reduces
hypersensitivity of BRCA1 mutant cells to PARP inhibitors and
leads to partial restoration of HR: in genetic terminology, 53BP1
loss is said to be ‘synthetic viable’ with BRCA1 deficiency (Aly
and Ganesan, 2011; Kaelin, 2005). The clinical significance of
these findings is still unclear: BRCA1-associated cancers often
exhibit reduced expression of 53BP1, which might have
predictive value as a potential biomarker of therapeutic
resistance to PARP inhibitors (Bouwman et al, 2010).
In addition to applying the SL concept to tumour suppressor
genes, an analogous strategy has been successfully implemen-
ted for dominantly acting oncogenes and specifically for KRAS.
Considering that KRAS is a widespread target in human
malignancies that remains substantially undruggable, the
inhibition of its putative synthetic lethal partners was
considered an affordable way to indirectly abrogate KRAS
pro-tumourigenic activity. Using diverse screening approaches,
several groups identified many putative SL interactors of KRAS.
Singh et al used RNAi to deplete the KRAS protein in lung and
pancreatic cancer cell lines harbouring mutated KRAS alleles;
this identified KRAS-dependent cells (which reacted to KRAS
silencing with growth impairment) and KRAS-independent cells
(whose proliferative activity was not affected by KRAS silencing,
despite the presence of activating KRAS mutations). The
KRAS-dependent cells were characterized by the expression
of proteins – including the tyrosine kinases SYK, RON, and
integrin b6 – that resulted in a differentiated epithelial
phenotype and that, when inactivated, induced epithelial–
mesenchymal transition and apoptosis (Singh et al, 2009). 2011 EMBO Molecular MedicineA high-throughput, RNAi-mediated SL screen in KRAS-
mutated cancer cells of different tissues revealed that the
serine/threonine kinase STK33 is selectively required in these
cells to sustain viability. This is mechanistically supported by the
observation that STK33 suppresses mitochondrial apoptosis via
S6K1-mediated inactivation of the pro-apoptotic effector BAD,
although the signalling intermediates between STK33 and S6K1
are still to be characterized (Scholl et al, 2009). With a similar
approach, Barbie et al discovered the anti-apoptotic role of the
non-canonical IkB kinase TBK1, an upstream activator of NF-kB
signalling, in KRAS-addicted cancer cell lines; this introduced NF-
kB-related signals as a ‘co-dependent’ survival pathway in KRAS-
mutated cancers (Barbie et al, 2009). An independent genome-
wide RNAi screen in isogenic cell lines differing only in the
presence or absence of a KRAS mutation identified 77 SL
candidate genes. Computational analysis supported an increased
dependency of mutated cells on proteins involved in the mitotic
machinery (e.g. polo-like kinase 1, PLK1) and the proteasome
suggesting that KRAS mutation is associated with mitotic stress;
intriguingly, gene expression analysis revealed a correlation
between decreased expression of key mitotic proteins and longer
survival of patients bearing tumours featuring a RAS transcrip-
tional signature (Luo et al, 2009). Finally, the effects of depletion
of different CDKs were studied in cells derived from mice
engineered to endogenously express a mutant KRAS allele and in
cell lines derived from KRAS mutated, non-small cell lung
carcinomas (NSCLCs). Selective loss of CDK4 had the most
prominent negative effect on the cancerous phenotype by
inducing a strong senescence response (Puyol et al, 2010).
The ultimate validation of all these SL strategies will be
evidence that patients with KRAS-mutated tumours clinically
benefit from treatment with inhibitors of the identified SL
partners. Selective CDK4 inhibitors are available for use in
humans but so far have shown only modest therapeutic efficacy
in unselected populations of patients with leukaemia or breast
tumours. Based on the novel results discussed here, such
inhibitors warrant future investigation in the context of KRAS-
mutated NSCLCs (Krystof and Uldrijan, 2010; Shapiro, 2006).
Similarly, PLK1 inhibitors are in the early phases of clinical
development and, likely, will soon be tested in patients with
KRAS-mutated cancers (Strebhardt, 2010).
Lastly, in addition to models that rely on cell-autonomous
properties, recent data from Felsher and colleagues suggest that
non-cell autonomous effects might deserve consideration in the
context of oncogene addiction and ‘synthetic lethal’ hetero-
logous cell–cell interactions. In particular, functional CD4þ
T-lymphocytes appear to be needed for efficient induction of
cellular senescence and/or inhibition of angiogenesis upon
inactivation of the MYC or BCR-ABL oncogenes in mouse
models of T cell acute lymphoblastic lymphoma and pro-B cell
leukaemia, respectively (Rakhra et al, 2010).The Clinical Correlates of Oncogene Addiction
Moving from reductionist approaches in oncogene-addicted cell
lines to cancer therapy in potentially oncogene-addictedEMBO Mol Med 3, 623–636 www.embomolmed.org
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Table 2. Targeted therapies in oncogene-addicted cancers
Name Target Disease FDA first
approval
Imatinib
mesylate
(Gleevec1)
BCR-ABL,
KITmut,
PDGFRmut
CML, GIST 2001
2002
Trastuzumab
(Herceptin1)
HER2ampl Breast cancer 1998
Erlotinib
(Tarceva1)
EGFRmut NSCLC 2004
Gefitinib
(Iressa1)
EGFRmut NSCLC 2003
Vemurafenib
(PLX4032)
BRAFmut Melanoma Phase 3
Crizotinib
(PF002341066)
ALKtransl NSCLC Phase 3
Iniparib
(BSI201)
PARP-1 BRCA-associated (hereditary)
or ‘BRCAness’-associated
(sporadic) breast and
ovarian cancer
Phase 2
Olaparib
(AZD2281)
PARP-1 BRCA-associated (hereditary)
or ‘BRCAness’-associated
(sporadic) breast and
ovarian cancer
Phase 2/3
mut, mutant; ampl, amplified; transl, translocated; CML, chronic myeloid
leukaemia; GIST, gastro-intestinal stromal tumour; NSCLC, non-small cell lung
cancer.tumours was a short step. In the past decade, the principle that
some tumours depend on one single oncoprotein for their
continuous growth – and the conclusion that this oncoprotein is
‘the’ target for therapeutic intervention – revealed itself as a
master rule in translational cancer research and provided a
rational framework to develop new targeted compounds for the
treatment of various cancer types (de Bono and Ashworth, 2010;
Stegmeier et al, 2010). This course of action is attested by a
series of successful clinical stories that illustrate the impact of
targeted therapeutics, when these are correctly used in selected
cohorts of patients harbouring oncogene-addicted tumours. In
the next paragraphs we will summarize the most relevant
clinical examples, including well-proven paradigms now
routinely applied to anti-cancer therapy and recent ‘from-
bench-to-bedside’ achievements (Table 2).
BCR-ABL in chronic myeloid leukaemia
The small Philadelphia (Ph) chromosome was characterized for
the first time in 1960 by Nowell and Hungerford as a peculiar
cytogenetic aberration correlated with chronic myelogenous
leukaemia (CML; Nowell & Hungerford, 1960). Little more than
a decade later, it was apparent that Ph carried a balanced
chromosomal translocation between the long arm of chromo-
some 9 (9q34) and the long arm of chromosome 22 (22q11),
which produces a fusion transcript between the breakpoint
cluster region-(BCR) and the gene coding for the Abelson (ABL)
tyrosine kinase (de Klein et al, 1982; Rowley, 1973). Numerous
reports followed providing convincing evidence that this
constitutively active chimeric protein has a driving role in the
pathogenesis and maintenance of CML; indeed, BCR-ALB waswww.embomolmed.org EMBO Mol Med 3, 623–636the first rock-solid example of an addictive oncoprotein in
human cancer at a time when the concept of oncogene addiction
was still to come (Sawyers, 2009). Not surprisingly, much effort
was then devoted to the search for chemical compounds able to
inhibit BCR-ABL. The small-molecule tyrosine kinase inhibitor
STI571 (imatinib; Gleevec1, Novartis) showed promising
results in pre-clinical models (Druker et al, 1996) and in
1998, the first Phase 1 study in chronic phase, Ph chromosome-
positive, CML patients started at three university institutions in
the United States. In almost 100% of patients, complete
haematologic responses were observed and these results were
confirmed in subsequent clinical studies. Even when clinical
trials were conducted on patients experiencing blast crisis,
the magnitude and frequency of clinical responses remained
remarkably high, indicating that BCR-ABL maintained its
causative function in sustaining malignant proliferation in all
the phases of the disease. Together, these more than promising
results led to the fast-track FDA approval of the drug in 2001
(Druker et al, 2001a, b).
Imatinib also selectively inhibits the receptor protein kinases
KIT and PDGFR. Again, an approach based on a strong rationale,
and some luck, led to the identification of activating mutations
of the KIT gene in approximately 90% of gastrointestinal stromal
tumours (GISTs); among KIT wild-type cases, 35% display
activating mutations in PDGFRA. These observations supported
the use of imatinib in advanced solid tumours, for which the
functional significance of driver mutations in the late phases of
disease was still a perplexing issue. As expected, FDA timely
approved the use of imatinib in GISTs in 2002 (Antonescu,
2011).
The development of imatinib was the chance for a paradigm
shift in the way cancer treatment was devised: medical
oncologists confronted with the notion that cancer is a disease
of genes not only at the molecular level, but also in terms of
therapeutic strategies. It is worth noting that the deliberation of
trialists to selectively recruit Ph chromosome-positive patients
was unprecedented and set the stage for genetically based
patient stratification, which today constitutes a cardinal
principle in targeted trial design. Moreover, imatinib develop-
ment was one of the first successes of medicinal chemistry
screening programs, which led to the in-depth characterization
of a small-molecule inhibitory compound against an oncogeni-
cally active tyrosine kinase (Lydon, 2009). Contrary to many
traditional chemotherapeutic drugs, the discovery of imatinib
was not a serendipitous occurrence but the long-sought result of
a productive collaboration between academia and industry.
Amplification of HER2 in breast cancer
HER2 (also known as ErbB2) is the ligandless member of the
EGFR family of receptor tyrosine kinases (RTKs). As much as
25–30% of breast cancers exhibit overexpression of the HER2
protein due to gene amplification, a feature that correlates with
adverse prognosis (Valabrega et al, 2007). Moreover, gain- and
loss-of-function approaches pointed to HER2 amplification as a
driving event in the onset and progression of mammary tumours
(Choudhury and Kiessling, 2004). The fact that a genetic
alteration with a prognostic significance also plays a causative 2011 EMBO Molecular Medicine 629
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630role in sustaining the mammary malignant phenotype made
HER2 an attractive target for therapeutic inhibition.
The first clinically relevant agent to block HER2 activity was a
humanized monoclonal antibody against the HER2 extracellular
domain (trastuzumab, Herceptin1, Genentech). Despite accu-
rate patient stratification based on assessment of HER2 protein
overexpression and/or gene amplification, only about 30% of
HER2-overexpressing metastatic breast cancer patients respond
to trastuzumab monotherapy (Valabrega et al, 2007). Thus,
HER2 amplification in breast cancer and BCR-ABL translocation
in CML share a common basis (the occurrence of a genetic lesion
that predicts response to its therapeutic inhibition) but they also
have important dissimilarities. CML is a ‘homogeneous’ disease
with a very high prevalence of the BCR-ABL translocation:
almost all patients display the genetic characteristic that predicts
response to imatinib, and almost all patients treated with
imatinib do in fact respond to treatment. Conversely, breast
cancer is a heterogeneous disease in which HER2 amplification
defines only a subset of tumours, and among HER2-amplified
tumours, responses are confined to only a fraction of cases.
Together, these observations suggest that the ‘addictive’
potency of HER2 amplification in breast cancer is weaker than
that of BCR-ABL in CML.
HER2-amplified tumours that do not respond to trastuzumab
feature a condition of so-called ‘primary’ or ‘de novo’ resistance,
which is commonly due to the concomitant activation of
alternative pathways that dominate over HER2 hyperactivation
or blunt HER2-dependent signals. Examples include parallel
activation of IGF1 receptor signalling, overexpression of EGF
family ligands and hyperactivation of PI3K-based transduction
cascades (Freudenberg et al, 2009). Consistently, a functional
RNAi screen identified downregulation of PTEN as a mechanism
of trastuzumab resistance. Activation of the PI3K pathway is
caused by oncogenic mutations in the PIK3CA gene, encoding
the catalytic subunit of PI3K, or loss of function of PTEN,
encoding the phosphatase that opposes PI3K activity. Either
condition is associated with poor prognosis after trastuzumab
therapy, and the combined analysis of PIK3CA and PTEN status
identifies twice as many patients at increased risk for
progression compared to PTEN stratification alone. Thus,
multi-parametric analysis of PI3K pathway activation may
provide a biomarker to identify patients unlikely to respond to
trastuzumab-based therapy (Berns et al, 2007; Stemke-Hale
et al, 2008).
Mutated EGFR in non-small cell lung cancer
The small-molecule compounds gefitinib (Iressa1, AstraZe-
neca) and erlotinib (Tarceva1, Roche) block the catalytic
activity of EGFR. Due to preliminary circumstantial evidence
describing EGFR overexpression in lung cancer, these inhibitors
were initially tested in unselected populations of non-small cell
lung cancer (NSCLC) patients. Results were disappointing: the
extent of clinical benefit from monotherapy with either drug
hovered near the threshold for statistical significance, with
response rates of approximately 10%, and the expected
endpoints were not reached. Yet, the minor subpopulation of
responsive patients had striking objective radiographic 2011 EMBO Molecular Medicineresponses and shared a number of clinical/epidemiologic
characteristics (adenocarcinoma histology, East Asian ethnicity,
a history of never smoking cigarettes and female gender),
suggesting a common molecular background (Sequist and
Lynch, 2008).
Retrospective genetic characterization of NSCLCs in respon-
ders and non-responders led to the seminal discovery that
specific EGFR kinase domain-activating mutations significantly
correlated with objective response to receptor inhibition. Once
more, this correlation highlighted the crucial importance of
mutationally activated kinases as anti-cancer drug targets. It
also identified a genetic marker for the subset of NSCLCs highly
responsive to EGFR inhibitors, providing momentum for the
rational design of clinical trials in selected, EGFR-mutated
patient cohorts. At least nine prospective studies involving
patients with advanced NSCLC and activating EGFR mutations
have substantiated the benefit of EGFR inhibition in EGFR-
mutant lung cancer, with 50–70% response rates and significant
improvements in progression free-survival (PFS) and overall
survival rates (Pao and Chmielecki, 2010). In 2009, gefitinib was
approved by the FDA for use in the advanced disease in all line
setting. The main lesson learnt from this example is that there
are cases in which targeted inhibition of tyrosine kinases is
effective in only a small subgroup of patients, and kinase
mutations represent the necessary predictors for patient
stratification. Moreover, the low frequency of genetically
defined responsive patient subsets raised the issue that a
reliable representation of genetic diversity requires the con-
sideration of a far broader sampling of individuals within a
specific cancer type than previously assumed. This poses
obvious logistical challenges for proper design, execution and
interpretation of clinical trials based on previously identified
molecules.
Similar to HER2, primary resistance also occurs in EGFR-
mutated cancers. This can be due to additional alterations in the
EGFR coding sequence, such as small insertions or deletions in
exon 20 and rare mutations co-existing with classical activating
mutations. Another mechanism, whereby, tumours with drug-
sensitive EGFR mutations may not respond to treatment with
EGFR inhibitors is the presence of other genetic lesions that
affect signalling downstream of EGFR, including activating
mutations in the PIK3CA gene or loss of PTEN expression (Pao
and Chmielecki, 2010).
Mutated BRAF in melanomas
The RAF family member B-RAF is a serine/threonine kinase that
is activated by RAS and, in turn, activates the MEK-ERK
pathway. The notion that the BRAF gene is mutated – with
variable frequencies – in many human tumour types dates back
to 2002 and, since then, a panel of somatic missense mutations
resulting in different levels of constitutive biochemical activity
has been described (Arkenau et al, 2011; Dhomen and Marais,
2007). Specifically, cutaneous melanomas display a 50–60%
prevalence of the V600E (BRAFV600E) mutated allele. The
widespread incidence of this genetic alteration, the high extent
of RAF catalytic hyperactivation produced by this amino acid-
specific mutation and its strong transforming properties in vitroEMBO Mol Med 3, 623–636 www.embomolmed.org
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melanomagenesis (Gray-Schopfer et al, 2007). In the past few
years, several small-molecule inhibitory compounds against
BRAF have been isolated. In particular, PLX4032 (Plexxikon),
which exhibits high selectivity specifically for the mutationally
activated BRAFV600E allele, showed promising results in the pre-
clinical setting. Accordingly, a Phase 1 trial with an extension
cohort reported 81% overall response rate (complete or partial
response) in mutated patients (Flaherty et al, 2010). Because of
this early promise, PLX4032 entered a Phase 3 trial directly after
Phase 1. The durability of response to PLX4032 is still under
evaluation (BRIM3 trial; ClinicalTrials.gov number
NCT01006980). Median PFS in the Phase 1 extension cohort
has been estimated to be at least 7 months, which compares
favourably with a PFS of less than 2 months in historical datasets
of advanced melanoma patients. However, tumour regrowth
has been documented to occur in many patients, which
underscores the frequent emergence of resistance in this
therapeutic setting (see below) and highlights the need for
improved long-term efficacy as a crucial goal of ongoing Phase 3
trials.
Interestingly, PLX4032 induces a paradoxical activation of the
RAF-MEK-ERK pathway upon inhibition of wild-type BRAF in a
RAS-mutant context due the formation of active BRAF–CRAF or
CRAF–CRAF dimers. This calls for caution regarding the use of
RAF inhibitors in RAS-mutant tumours, including a minority of
melanomas that harbour RAS alterations (Poulikakos and
Rosen, 2011).
EML4-ALK in non-small cell lung cancer
The most recent insight into the successful clinical application of
the oncogene addiction principle is the use of a small molecule
inhibitor of ALK (anaplastic lymphoma kinase) in NSCLC
patients. In 2007, a small interstitial deletion and inversion
within chromosome 2p [inv(2)(p21:p23)] was identified that
results in the synthesis of a fusion protein between EML4
(echinoderm microtubule-associated protein like-4) and ALK in
2–7% of NSCLCs. Biochemical and functional experiments
revealed that the fusion protein harbours a constitutively active
ALK and exhibits tumourigenic potential (Sasaki et al, 2010).
Despite the appreciably lower incidence of ALK mutations in
NSCLCs when compared, for example to mutated BRAF alleles
in melanomas, the strong oncogenic activity of EML4-ALK
offered a solid pre-clinical rationale for therapeutic targeting
(McDermott et al, 2008). The ALK inhibitor PF-02341066
(crizotinib, Pfizer) has produced excellent results in a Phase 1
trial in NSCLC patients, with a 57% response rate in 82 ALK-
rearranged patients (Kwak et al, 2010). Rates of disease control
(response or stable disease for at least 8 weeks) exceeded 90%
with negligible toxicity. Similar to the case of BRAF inhibition in
BRAF-mutant melanomas, the compelling nature of these
findings prompted the execution of a Phase 3 trial without an
intermediate Phase 2 study (Gerber and Minna, 2010).
The rapid implementation of Phase 1 information into large,
randomized Phase 3 trials is a clear sign of the power of early
studies when these are supported by a strong biological
rationale and by highly significant responses. However, thewww.embomolmed.org EMBO Mol Med 3, 623–636ethical aspects of such an accelerated procedure remain
controversial: if patients with incurable disease, whose tumour
have the addictive mutation, are informed of the efficacy of the
experimental drug, they will want (and deserve) access to the
new treatment and may not accept random assignment to a
poorly effective and toxic conventional therapy. This challenge
is one of the many thorny issues that oncologists have to face
when dealing with potentially effective targeted therapies
(de Bono and Ashworth, 2010).
PARP-1 in ovarian and ‘triple negative’ breast cancer
As discussed above, PARP-1 inhibition is synthetic lethal in
combination with faulty HR mechanisms. A Phase 1 trial
conducted in 2009 demonstrated the anti-tumour activity of the
small-molecule PARP inhibitor olaparib (AstraZeneca) in a
population of cancer patients (ovarian, breast and prostate)
enriched for BRCA1 or BRCA2 mutations, with BRCA mutation
carriers exhibiting radiographic response or meaningful disease
stabilization (stable disease for a period of 4 months or more;
Fong et al, 2009).
Triple-negative breast cancer (estrogen receptor-negative,
progesterone receptor-negative and not overexpressing HER2) is
an aggressive subtype of breast cancer that shares clinical and
pathological characteristics with hereditary BRCA1-related
mammary tumours. In sporadic triple-negative breast cancer,
the function of BRCA1 is defective due to promoter hyper-
methylation, overexpression of negative regulators or other
defects in HR pathways. Together, these alterations define a
context of ‘BRCAness’ that suggests SL with PARP inhibitors.
Indeed, a Phase 2 study compared the efficacy of a classical
platinum-containing doublet with or without the PARP inhibitor
iniparib (Sanofi Aventis) in a cohort of patients with advanced
triple-negative breast cancers, documenting an increase in
overall response rate from 32 to 52% with the addition of
iniparib to chemotherapy (O’Shaughnessy et al, 2011). How-
ever, interim results from a Phase 3 trial, which were made
available to the public in early 2011, were disappointing: similar
to the Phase 2 study, the drug was used in a randomized trial
with patients receiving gemcitabine and carboplatin with or
without iniparib. No improvement in overall survival or
progression-free survival was found in patients receiving
iniparib as a first-line therapy (ClinicalTrials.gov number:
NCT00938652). Likely, the increase in the size of the study
population that characterizes Phase 3 trials has somehow
diluted the occurrence of the BRCAness phenotype in triple-
negative breast cancers, and specific response biomarkers are
needed for better patient stratification.A Common Theme: The Emergence of Secondary
Resistance
The emergence of secondary (acquired) resistance at some point
during treatment soon became apparent when a clinical trial of
imatinib in blast-crisis CML patients showed that some subjects
had developed clinical insensitivity to the drug after remarkable
but transient remission. Initial studies indicated that the average 2011 EMBO Molecular Medicine 631
Review
Oncogene addiction and targeted anti-cancer therapy
632chronic-phase patient using imatinib has a risk of approximately
10%/year of relapsing into blast crisis. Analysis of BCR-ABL
sequences in the myeloid clones of patients with imatinib-
resistant, relapsed disease indicated a high frequency of
mutations in the BCR-ABL gene. The prototypic amino-acid
substitution (T315I) produces a steric hindrance in the ATP-
binding pocket of the kinase, which interferes with insertion of
imatinib into the cavity (‘gatekeeper mutation’). Other muta-
tions lock the BCR-ABL kinase domain in an active position,
preventing binding of imatinib (Shah and Sawyers, 2003). In this
case, chemicals able to bind this conformation are expected to
achieve full inhibitory potential. At least two molecules, dasatinib
(Sprycel1, Bristol-Myers Squibb) and nilotinib (Tasigna1,
Novartis), display this property and are now used for the
treatment of relapsing, resistant CML patients. In a minority of
cases, imatinib resistance results from amplification of the BCR-
ABL gene, which leads to increased levels of the corresponding
protein product (Engelman and Settleman, 2008).
The acquisition of secondary mutations that prevent drug
binding to the kinase catalytic cleft has been documented as a
cause of secondary resistance also for other targets and in other
oncogene-addicted tumours, including mutant EGFR and EML4-
ALK in NSCLCs as well as mutant c-KIT in GISTs (Engelman and
Ja¨nne, 2008; Stegmeier et al, 2010). Alternatively, other
oncogenes can undergo genetic alterations to produce aberrant
signalling in lieu of the pathways that are no longer sustained by
the inhibited target. Some gefitinib-resistant NSCLCs, for
example harbour amplifications of the MET oncogene, which
triggers PI3K survival signals via trans-phosphorylation of
ERBB3 (Engelman et al, 2007). As previously discussed, BRAF-
mutant melanomas treated with RAF inhibitors tend to regrow
and progress after excellent initial response. A number of recent
papers have revealed potential mechanisms of acquired
resistance to RAF inhibitors: again, these mechanisms entail
genetic alterations that circumvent target blockade by acting
either on the target itself (BRAF amplification) or on analogous
pathways (NRAS amplification or overexpression of COT, a
MAPK pathway agonist). Some of these resistance-inducing
alterations have been also detected in tumour material from
relapsed patients (reviewed in Poulikakos and Rosen, 2011).
The common theme of all these examples is that the
inactivated target is bypassed by compensating lesions that
may act either in a vertical or horizontal fashion: in the former
model, secondary alterations within the same upstream target
re-stimulate the downstream signalling flux along the same,
previously inhibited pathway; in the latter, parallel axes are
activated that substitute for the blocked signalling (Fig 3B
and C). Thus, genetic instability may fuel the appearance of
oncogenic lesions that are evolutionarily selected to drive
tumour survival and growth upon the selective pressure of drug
exposure. In this scenario, an intriguing hypothesis is that
secondary resistance is in fact nothing but the clonal selection of
a minor subpopulation of cells that pre-exist before treatment
and harbour a priori resistant alleles: drug exposure eliminates
the bulk of sensitive cells, eventually leading to expansion of the
resistant clones. This assumption was experimentally validated
in several tumour settings (Fig 3A). At least some imatinib- 2011 EMBO Molecular Medicineresistant CML clones are thought to occur at low frequency prior
to treatment and experience clonal selection upon imatinib
exposure (Hofmann et al, 2003; Shah et al, 2002). Similarly, the
EGFR T790M mutation can be detected at low levels in patients
with EGFR-mutant NSCLCs (Maheswaran et al, 2008). Finally,
rare cells exhibiting amplification of the MET oncogene are
present in NSCLCs before drug exposure. Such cells are
intrinsically resistant to EGFR inhibitors and emerge during
the course of therapy through a positive selection process that is
dramatically accelerated by the environmental availability of the
Met ligand HGF (Turke et al, 2010).
Other mechanisms of drug resistance have been demon-
strated at the pre-clinical level. The concept that cancer cell
populations are inherently heterogeneous and that individual
cells respond differently to drug treatment has been supported
by the finding that human cancer cell lines contain a small
subpopulation of reversibly ‘drug-tolerant’ cells, displaying
reduced drug sensitivity only for a limited period of time. This
transient condition requires IGF1-R signalling and an altered
chromatin state, which indicates that this phenomenon is
chiefly sustained by epigenetic, rather than genetic, mechanisms
(Sharma et al, 2010a). Similar to antibiotic-tolerant bacterial
strains, which also display a provisional ability to bear potentially
lethal stresses, the reversible insensitivity of drug-tolerant cells to
initial drug exposure likely allows the production of more stable
resistance mechanisms. Whether this dynamic switch between
reversibly tolerant and sensitive tumour subpopulations also
occurs in vivo in drug-treated tumours remains to be established.Outlook
Since its inception, the concept of oncogene addiction was
widely accepted amongst molecular oncologists. Maybe for the
first time in cancer research, biological evidence has been
almost directly implemented into an operative vision for the
rational treatment of cancer. Yet, experimental and clinical facts
raise a number of issues that warrant further investigation. For
example the biological outcomes produced by inhibition of
oncogene-addicted cells (cell-cycle arrest, senescence, differ-
entiation or apoptosis) appear to be context-dependent, and the
signalling circuitries beneath these cell-specific responses still
have to be explored. Understanding the mechanisms that
regulate cytostatic versus cytotoxic responses will have
important therapeutic implications. Although extensive, our
knowledge of signalling networks is still rudimentary. We
believe that worthwhile information will be provided by the
ongoing development of new technologies for large-scale,
unbiased analyses: genome-wide functional screens, deep
sequencing, mass spectrometry and advanced imaging
approaches will offer extensive ground for hypothesis genera-
tion and for additional target discovery. From a mechanistic
perspective, we predict that the incoming technological
armamentarium will encourage a switch from an oncogene-
centered to a network-based interpretation of data; this, in turn,
will likely provide full awareness of the complex cellular circuits
that generate and maintain oncogene addiction.EMBO Mol Med 3, 623–636 www.embomolmed.org
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Figure 3. Models of secondary resistance.
A. When the addictive oncoprotein is inhibited, viability is seriously compromised and cancer cells stop proliferating or die (middle). Addiction to a certain
oncogene might not be a homogeneous characteristic of the cancer cell population, and drug-insensitive subclones (top and bottom) may co-exist with
sensitive cells.
B, C. Fuelled by genomic instability, targeted treatment of addicted cells may result in induction (arrows, solid line) of secondary resistance through either
mutation (star) or amplification/overexpression of relevant signalling nodes. This may happen in a vertical fashion, by alterations involving downstream
effectors of the original addictive pathway (B), or in a horizontal fashion, when a parallel signalling axis surrogates target blockade (C). If resistant clones are
already present at the beginning of treatment (panel A), these may be selected by drug exposure (arrows, dashed line) until they outcompete sensitive cells,
resulting in ‘acquired’ resistance as well.At the clinical level, much remains to be done to optimize
molecular information for patient stratification and treatment
during trial execution. Experimental drugs are typically assessed
in patients with late-stage disease and often for compassionate
treatment, when all prior therapies with standard agents have
failed. While ethically impeccable, this approach inevitably
underestimates the effects that the same investigational
drug could exert in less advanced cancers. Detection of
predictive biomarkers requires genetic or expression
analysis on tumour material; similarly, assessment of pharma-
codymanic biomarkers (which measure the near-term treatment
effects of a drug on its target) may imply acquisition of
bioptic samples. Because these assays are preferably carried
out concomitantly with therapy, re-biopsy approaches shouldwww.embomolmed.org EMBO Mol Med 3, 623–636be encouraged. However, the clinical trial community is
reluctant to design studies that require additional tissue
samples due to reasonable concerns about more difficult
patient enrolment. We appreciate that, when moving from
the preclinical to the clinical setting, the ethical and logistical
challenges become enormous; but we also believe that the
psychological and physical burden that patients will bear for
standardized provision of human material will be rewarded by
application of better personalized therapies. ‘Flexible’ and
‘adaptive’ trials, in which molecular information and clinical
data are handled quickly and effectively for real-time assign-
ment of each individual to the most suitable therapeutic
regimen, will be key to increasing life expectancy in cancer
patients. 2011 EMBO Molecular Medicine 633
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Pending issues
Mechanistic/computational studies aimed at better defining the
network architecture of the pathways that sustain oncogene addic-
tion.
Detailed cataloging and characterization of the mechanisms under-
lying primary and secondary resistance in cells, animal models and
humans.
‘Adaptive’ trial format design, favouring fast and easy validation of
clinical observations in the laboratory as well as streamlining of
experimental information from bench-to-bedside.
Development of new reliable biomarkers of response to targeted
agents to optimize real-time patient stratification.
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